4.3 Review

A Woman's Heart: Improving Uptake and Awareness of Cardiovascular Screening for Middle-Aged Populations

期刊

INTERNATIONAL JOURNAL OF WOMENS HEALTH
卷 15, 期 -, 页码 1171-1183

出版社

DOVE MEDICAL PRESS LTD

关键词

women's health; mid-life; risk assessment; cardiovascular disease; prevention; menopause

向作者/读者索取更多资源

Mid-life in women is marked by changes in cardiometabolic risk factors, making it a critical time for cardiovascular disease (CVD) risk assessment. It is important to evaluate traditional risk factors and reproductive history to identify female-specific factors that contribute to CVD risk. In cases of uncertainty, measuring a coronary artery calcium score can help refine risk assessment. Additionally, there is a need to improve the recognition of ischemic heart disease in women and incorporate novel risk factors into CVD assessment. This review provides an approach to CVD screening and risk assessment in middle-aged women.
Mid-life, the years leading up to and following the menopause transition, in women is accompanied by a change in cardiometabolic risk factors, including increases in body weight, changes in body composition, a more insulin-resistant state, and a shift towards a more atherogenic dyslipidemia pattern. Cardiovascular disease (CVD) risk assessment should be performed continually throughout the lifespan, as risk is not stagnant and can change throughout the life course. However, mid-life is a particularly important time for a woman to be evaluated for CVD risk so that appropriate preventive strategies can be implemented. Along with assessing traditional risk factors, ascertainment of a reproductive history is an integral part of a comprehensive CVD risk assessment to recognize unique female-specific or female-predominant factors that modify a woman's risk. When there is uncertainty about CVD risk and the net benefit of preventive pharmacotherapy interventions (such as statins), measuring a coronary artery calcium score can help further refine risk and guide shared decision-making. Additionally, there should be heightened sensitivity around identifying signs and symptoms of ischemic heart disease in women, as these may present differently than in men. Ischemia from coronary microvascular disease and/or vasospasm may be present even without obstructive coronary artery disease and is associated with a heightened risk for major cardiovascular events and reduced quality of life. Therefore, correctly identifying CVD in women and implementing preventive and treatment therapies is paramount. Unfortunately, women are underrepresented in cardiovascular clinical trials, and more data are needed about how to best incorporate novel and emerging risk factors into CVD risk assessment. This review outlines an approach to CVD screening and risk assessment in women using several methods, focusing on the middle-aged population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据